Company news
Tiziana Life Sciences Ltd news in 2021
Tiziana Life Sciences Ltd's news releases, calls and decks from 2021, newest first.
Share Capital Consolidation and Commencement of trading in the New Tiziana Shares on NASDAQ
October 20, 2021
Tiziana Life Sciences - Scheme Effective Date
October 19, 2021
Tiziana Life Sciences Plc - Results of Court Meeting and General Meeting
September 26, 2021
Tiziana Life Sciences plc - Interim Results for the Six Months Ended 30 June 2021
September 23, 2021
Tiziana Life Sciences plc Posting of Scheme Document and Notice of Meetings
September 2, 2021
Tiziana Life Sciences plc files scheme of arrangement to effect a corporate reorganisation and, if approved, the delisting of its ordinary shares in London and the direct listing of common shares in the new parent company of the Tiziana group on NASDAQ
August 19, 2021
Tiziana Announces Publication of a Peer Reviewed Article on Data from the Clinical Trial with Intranasally Administered Foralumab, Its Proprietary Fully Human Anti-CD3 Monoclonal Antibody, in Mild to Moderate COVID-19 Patients in Brazil
August 16, 2021
Tiziana Life Sciences plc (the "Company") Result of Annual General Meeting
June 24, 2021
Tiziana Enters a Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
June 22, 2021
Tiziana Appoints Dr. Kevin Schutz as Vice-President of Regulatory Affairs
June 20, 2021
Tiziana Life Sciences plc ("Tiziana" or the “Company”) Posting of Notice of Annual General Meeting
June 1, 2021
Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers
May 25, 2021
Tiziana Life Sciences Announces Initiation of Clinical Trial in a Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access P...
May 24, 2021
Tiziana Announces Strategic Initiative with Takanawa Japan K.K., Pharma Team, to Identify a Partner in Japan and Other Asian Countries for Further Clinical Development of Milciclib in Patients with Advanced Hepatocellular Carcinoma.
May 4, 2021
Tiziana Life Sciences plc Announces Plans to List Accustem Sciences Limited in the U.S.
April 12, 2021
Tiziana Announces the FDA Has Allowed Treatment for a Secondary Progressive Multiple Sclerosis (SPMS) Patient for the Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program
March 29, 2021
Tiziana Life Sciences plc ("Tiziana" or the "Company") - Appointment of Director
February 4, 2021
Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil
February 1, 2021
Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana Files Registration Statement on Form F-3 with U.S. Securities and Exchange Commission
January 26, 2021
Tiziana Life Sciences plc ("Tiziana" or the "Company") - AIM Delisting and Admission to the Standard Listing Segment of Main Market
January 19, 2021
Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer
January 12, 2021
Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in Brazil
January 3, 2021